drugset
drugset / Trial / NCT04677530

A Study of JNJ-40411813 in Healthy Japanese Male Participants

NCT04677530 ↗

Phase 1 Completed 39 enrolled Janssen Pharmaceutical K.K.
RandomizedSequentialDouble-blindOther

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) after single dose and multiple dose administrations of JNJ-40411813 in Japanese healthy adult male participants.

Timeline

Start
2021-01-29
Primary completion
2021-05-21
Completion
2021-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-40411813 Small molecule — Oral

Indications

No indication recorded.